{"DataElement":{"publicId":"7391868","version":"1","preferredName":"Pegaspargase Discontinued Reason","preferredDefinition":"The response to a question asking for the reason for discontinuing pegaspargase.","longName":"PEG_DISC_RSN","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"7391862","version":"1","preferredName":"Pegaspargase Discontinue","preferredDefinition":"A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)_To stop or end, permanently or temporarily.","longName":"7391860v1.0:2433916v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"7391860","version":"1","preferredName":"Pegaspargase","preferredDefinition":"A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)","longName":"C1200","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pegaspargase","conceptCode":"C1200","definition":"A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACC9791F-8A7D-4343-E053-4EBD850AD386","latestVersionIndicator":"Yes","beginDate":"2020-08-13","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-08-13","modifiedBy":"ONEDATA","dateModified":"2020-08-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2433916","version":"1","preferredName":"Discontinued","preferredDefinition":"Discontinued; stopped permanently or temporarily.","longName":"C25484","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Discontinue","conceptCode":"C25484","definition":"To stop or end, permanently or temporarily.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"06674CCB-CDA9-04A9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-28","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-28","modifiedBy":"ONEDATA","dateModified":"2005-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACC9791F-8A8B-4343-E053-4EBD850AD386","latestVersionIndicator":"Yes","beginDate":"2020-08-13","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-08-13","modifiedBy":"SETRAKIN","dateModified":"2020-08-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7391864","version":"1","preferredName":"Asparaginase Discontinued Reason","preferredDefinition":"An explanation of the cause of some phenomenon or action.","longName":"7391864v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"30","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"3126125","version":"1","preferredName":"Other","longName":"3126125","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8D01180C-814A-B8B4-E040-BB89AD432507","latestVersionIndicator":"Yes","beginDate":"2010-08-04","endDate":null,"createdBy":"MAESKEB","dateCreated":"2010-08-04","modifiedBy":"KUMMEROA","dateModified":"2023-03-07","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/03/2015.","administrativeNotes":"2023.3.7 Alt VM added per ticket request CADSR0002119. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ACC97179-89D1-2BC4-E053-4EBD850AE7E5","beginDate":"2020-08-13","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-08-13","modifiedBy":"ONEDATA","dateModified":"2020-08-13","deletedIndicator":"No"},{"value":"Drug shortage","valueDescription":"Drug shortage","ValueMeaning":{"publicId":"7391865","version":"1","preferredName":"Drug shortage","longName":"7391865","preferredDefinition":"Drug shortage","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACC97179-89DB-2BC4-E053-4EBD850AE7E5","latestVersionIndicator":"Yes","beginDate":"2020-08-13","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-08-13","modifiedBy":"ONEDATA","dateModified":"2020-08-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ACC97179-89F4-2BC4-E053-4EBD850AE7E5","beginDate":"2020-08-13","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-08-13","modifiedBy":"ONEDATA","dateModified":"2020-08-13","deletedIndicator":"No"},{"value":"Stroke","valueDescription":"Stroke","ValueMeaning":{"publicId":"2570732","version":"1","preferredName":"Stroke","longName":"2570732","preferredDefinition":"Stroke","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E159-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ACC97179-89FE-2BC4-E053-4EBD850AE7E5","beginDate":"2020-08-13","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-08-13","modifiedBy":"ONEDATA","dateModified":"2020-08-13","deletedIndicator":"No"},{"value":"Pancreatitis","valueDescription":"Pancreatitis","ValueMeaning":{"publicId":"2559694","version":"1","preferredName":"Pancreatitis","longName":"2559694","preferredDefinition":"Inflammation of the pancreas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreatitis","conceptCode":"C3306","definition":"Inflammation of the pancreas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B63B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ACC97179-8A08-2BC4-E053-4EBD850AE7E5","beginDate":"2020-08-13","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-08-13","modifiedBy":"ONEDATA","dateModified":"2020-08-13","deletedIndicator":"No"},{"value":"Systemic allergic reaction","valueDescription":"Systemic allergic reaction","ValueMeaning":{"publicId":"7391866","version":"1","preferredName":"Systemic allergic reaction","longName":"7391866","preferredDefinition":"Systemic allergic reaction","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACC97179-8A12-2BC4-E053-4EBD850AE7E5","latestVersionIndicator":"Yes","beginDate":"2020-08-13","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-08-13","modifiedBy":"ONEDATA","dateModified":"2020-08-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ACC97179-8A2B-2BC4-E053-4EBD850AE7E5","beginDate":"2020-08-13","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-08-13","modifiedBy":"ONEDATA","dateModified":"2020-08-13","deletedIndicator":"No"},{"value":"Local allergic reaction","valueDescription":"Local allergic reaction","ValueMeaning":{"publicId":"7391867","version":"1","preferredName":"Local allergic reaction","longName":"7391867","preferredDefinition":"Local allergic reaction","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACC97179-8A35-2BC4-E053-4EBD850AE7E5","latestVersionIndicator":"Yes","beginDate":"2020-08-13","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-08-13","modifiedBy":"ONEDATA","dateModified":"2020-08-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ACC97179-8A4E-2BC4-E053-4EBD850AE7E5","beginDate":"2020-08-13","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-08-13","modifiedBy":"ONEDATA","dateModified":"2020-08-13","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2240632","version":"1","preferredName":"Reason","preferredDefinition":"An explanation of the cause of some phenomenon or action.","longName":"C25638","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Reason","conceptCode":"C25638","definition":"An explanation of the cause of some phenomenon or action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F9FA7953-8391-043D-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-30","endDate":null,"createdBy":"PWEST","dateCreated":"2005-06-30","modifiedBy":"ONEDATA","dateModified":"2005-06-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACC97179-89BA-2BC4-E053-4EBD850AE7E5","latestVersionIndicator":"Yes","beginDate":"2020-08-13","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-08-13","modifiedBy":"SETRAKIN","dateModified":"2020-08-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"Reason for discontinuing Pega","type":"Preferred Question Text","description":"Reason for discontinuing Pegaspargase:","url":null,"context":"COG"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Reason for discontinuing Pegaspargase/Calaspargase","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACC97179-8A58-2BC4-E053-4EBD850AE7E5","latestVersionIndicator":"Yes","beginDate":"2020-08-13","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-08-13","modifiedBy":"WOODC","dateModified":"2020-12-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}